Phase 2 TALENT Trial: Talazoparib as Monotherapy or With Enzalutamide in HRR-deficient mCRPC

/in , , /by

The TALENT trial is a randomized, open‑label, phase 2 trial evaluating whether adding enzalutamide to talazoparib improves outcomes compared with talazoparib alone in men with metastatic castration‑resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) gene alterations and have progressed after abiraterone‑based therapy. The trial builds on the phase 3 TALAPRO‑2 results, which showed […]

Read more

ABBV-969 in mCRPC: Dual‑Targeting ADC Shows Robust PSA and Objective Responses in Heavily Pretreated Patients

/in , , /by

ABBV-969, a first-in-class dual-targeting antibody-drug conjugate (ADC), is emerging as a promising new therapeutic candidate for patients with metastatic castration-resistant prostate cancer (mCRPC), particularly in the late-line setting where treatment options are limited and outcomes remain poor. Designed to simultaneously target prostate-specific membrane antigen (PSMA) and six-transmembrane epithelial antigen of prostate 1 (STEAP1), both highly […]

Read more

CONVERGE-01: CONV01-α Shows Activity After Lu-PSMA in mCRPC

/in , , /by

Actinium-225 rosopatamab tetraxetan (CONV01-α) is a PSMA-targeted alpha radioligand therapy being tested in men with metastatic castration-resistant prostate cancer who have already received androgen receptor pathway inhibitors, up to one taxane regimen, and 1–6 cycles of lutetium-177 PSMA therapy (Pluvicto), with all patients having PSMA PET–positive disease by VISION criteria. The drug links an alpha […]

Read more

Overcoming AR Mutations in Prostate Cancer: Phase 1 Results of HRS-5041

/in , , /by

A new investigational drug, HRS-5041, may offer a compelling strategy to overcome resistance to androgen receptor (AR)-targeted therapies.. Unlike traditional AR inhibitors, HRS-5041 is an oral androgen receptor degrader designed to eliminate the receptor itself, including clinically relevant mutant forms. In a phase 1, 156 patients with mCRPC were treated with HRS-5041. All patients had […]

Read more

BAT Before Sipuleucel-T in mCRPC: Immune Priming?

/in , , /by

Bipolar androgen therapy (BAT) given before sipuleucel‑T appears to increase the rate and magnitude of PA2024‑specific immune responses in men with metastatic castration‑resistant prostate cancer (mCRPC), compared with historical sipuleucel‑T data. The central interpretation is not that BAT by itself generates this immune response, but that BAT may prime the tumor and immune environment so […]

Read more

ARPI Doublet vs Triplet Therapy in Metastatic Prostate Cancer: Real‑World Survival and the Role of PSA Nadir

/in /by

Therapy intensification in metastatic prostate cancer has expanded the repertoire of combination regimens, but it remains unclear which patients truly benefit from adding upfront docetaxel to an androgen receptor pathway inhibitor (ARPI) based doublet. A large real world cohort study using the U.S. based Patient360 Prostate dataset, which aggregates de identified electronic health records, linked […]

Read more

Emerging Real-World Evidence Suggests Differential Outcomes Between Abiraterone and Darolutamide in Hormone-Sensitive Prostate Cancer

/in /by

Agents such as abiraterone and darolutamide have demonstrated significant survival benefits in randomized clinical trials, yet direct comparative evidence between these therapies, particularly in the pre-chemotherapy setting, remains notably absent. A recent retrospective cohort analysis leveraging the TriNetX database attempts to address this gap by comparing real-world outcomes in patients treated with ADT plus either […]

Read more

Darolutamide Linked to Cognitive Benefit Over Enzalutamide in Prostate Cancer

/in , , , , /by

Darolutamide (Nubeqa) caused significantly less cognitive decline than enzalutamide (Xtandi) over 24 weeks in men with advanced prostate cancer, according to results from the phase 2 ARACOG trial, which are scheduled to be presented at the 2026 ASCO Annual Meeting. The findings represent the first randomized, prospective head-to-head comparison of the cognitive effects of two […]

Read more

CT‑Measured Muscle Quality Predicts Survival in Men with Non‑Metastatic Castration‑Resistant Prostate Cancer

/in /by

Researchers in Japan have found that muscle “quality,” not just size, is linked to how long men with non‑metastatic castration‑resistant prostate cancer (nmCRPC) live, even when they are treated with androgen receptor signaling inhibitors. The study analyzed 344 men using standard CT scans to measure muscle quantity and the amount of fat inside the muscle, […]

Read more

When Scans Stay Stable: How Progression‑Free Survival Reflects Survival in mCRPC

/in /by

At the 2026 American Urological Association (AUA) Annual Meeting, researchers showed that radiographic progression‑free survival (rPFS), the time from treatment start until scans show clear cancer progression or death, is a strong and meaningful reflection of overall survival in men with metastatic castration‑resistant prostate cancer (mCRPC). Using individual‑patient data from the large TALAPRO‑2 trial, they […]

Read more